Inhalon Biopharma, Inc.

Session Title: Update in Emerging Infectious Diseases of Military Importance: Predicting and Preventing Future Outbreaks in Military Settings Poster Title: Nebulization Provides Superior Delivery of an Antiviral Monoclonal Antibody Compared to Intravenous Infusion Session Date & Time: August 28, 2024, 10 a.m. Session Title: Update in Emerging Infectious Diseases of Military Importance: Predicting and Preventing Future Outbreaks in Military Settings Poster Title: Development of an Antibody Fusion Protein as a Pan-Variant, Warfighter-Friendly, Decoy Therapeutic to Address Outbreaks with Pandemic Potential Session Date & Time: August 28, 2024, 10 a.m.

​ ​ ​Durham, North Carolina, June 3, 2024 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at the BIO International Convention being held June 3-6, 2024, in San Diego, Calif. In his presentation, company CEO John Whelan will discuss the company’s recently announced data on the success of inhaled monoclonal antibodies in treating acute respiratory infections, including a Phase 1b study on IN-006, demonstrating the superiority of inhaled antibody delivery over intravenous (IV) or intramuscular (IM) delivery, and preclinical studies published in Advanced Science and Bioengineering and Translational Medicine. “Amid concerns about emerging pathogens like H5N1, and with lessons learned during the recent COVID-19 pandemic fresh in everyone’s minds, there’s a clear sense that the health care ecosystem needs to be able to quickly develop, manufacture and easily deploy effective treatments for respiratory infections,” said John Whelan, chief executive officer of Inhalon Biopharma. “Our inhaled antibody platform is ideal for this application. We’ve repeatedly shown it to be capable of delivering antibodies directly to the site of infection in the respiratory tract, including the deep lung. Further, because this type of treatment can be administered in a patient’s home, it has the potential to address many of logistical challenges that have hindered access to other antibody-based therapies.” Inhalon Biophama is developing inhaled antibody products as potential treatments for a range of acute respiratory infections including respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza. This treatment approach involves the delivery of antibody therapy directly to the site of infection, using a handheld nebulizer rather than systemically via an oral or intravenous delivery approach. Such a treatment approach is believed to reduce costs and ease the burden of care on patients and the health care system. Presentation Details Date: June 3, 2024 Time: 3:15-3:30 p.m. PT Location: Company Presentation Theater 3 About Inhalon Biopharma Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC. ​ John Whelan jbwhelan@inhalon.com Media Gwen Gordon gwen@gwengordonpr.com ​​

Back to News ​ ​ ​Durham, North Carolina, April 25, 2024 — Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced plans to present at the 9th Annual Inhalation and Respiratory Drug Delivery Congress on April 26, 2024, in London, UK. The presentation, “Pre-clinical and clinical experience with inhaled muco-trapping antibodies against respiratory infections,” will be the keynote address on the “Innovations & novel approaches in inhaled therapies, delivery & device development track.” During the presentation, Inhalon Biopharma founder, chief scientific officer and director Sam Lai, Ph.D., will discuss the company’s progress in advancing its pipeline of inhaled treatments for acute respiratory infections. He will detail recent progress including highlights from a recently completed Phase 1b study comparing inhaled delivery vs. intravenous delivery, and preclinical studies published in Advanced Science and Bioengineering and Translational Medicine. “Since I founded Inhalon Biopharma in 2018, we’ve made tremendous strides towards developing the evidence to support the use of inhaled antibodies to treat respiratory infections,” said Sam Lai, Ph.D., said founder and chief scientific officer of Inhalon Biopharma. “We’ve repeatedly shown in preclinical models, and now in humans, that antibodies can be effectively delivered to the respiratory tract via inhalation, and our studies have upended conventional wisdom about this form of delivery’s ability to reach the deep lung.” Inhalon Biophama is developing inhaled antibody products as potential treatments for respiratory syncytial virus (RSV), SARS-CoV-2, metapneumovirus (hMPV), and influenza. This treatment approach involves the delivery of antibody therapy directly to the site of infection, using a handheld nebulizer rather than systemically via an oral or intravenous delivery approach. Such an approach is believed to reduce costs and ease the burden of care on patients and the health care system. About Inhalon Biopharma Inhalon Biopharma is a clinical-stage company advancing a proprietary inhaled antibody platform for treating a variety of acute respiratory infections. Inhalon Biopharma’s intellectual property includes approved U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Life Science Angels, and JSR Life Sciences as well as several federal grants from the NIH and USAMRDC. ​ John Whelan jbwhelan@inhalon.com Media Gwen Gordon gwen@gwengordonpr.com ​​